Gland Pharma secures USFDA approval for eye care drug Olopatadine 0.7%, stock up 5%Gland Pharma secures USFDA approval for eye care drug Olopatadine 0.7%, stock up 5%

Introduction

Leading pharmaceutical company receives USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC), equivalent to Pataday, for treating ocular itching associated with allergic conjunctivitis.

Also Read: Kalyan Jewellers posts 42% growth in Q3, shares up 7% post result

Share price movement of Gland Pharma

On January 8, 2026, Gland Pharma Ltd opened at ₹1,743.05, up 2.03% from its previous close of ₹1,708.50. The stock reached a high of ₹1,795.85 (5.15%) and a low of ₹1,702.00 (-0.38%). By 12:40 PM, it traded at ₹1,704.85, a -0.21% decrease, with a market cap of ₹28,088.50 crore.

Gland Pharma Receives USFDA Approval for Ophthalmic Solution

Gland Pharma Limited received approval from the U.S. FDA for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is therapeutically equivalent to Pataday Once Daily Relief, 0.7%.

The solution is indicated for treating ocular itching associated with allergic conjunctivitis. This approval strengthens Gland Pharma’s ophthalmic portfolio and enables the company to market the product in the U.S. market.

Stock performance of Gland Pharma for Period of 1 week, 6 months, and 1 year

Gland Pharma Ltd delivered a -0.39% return over the past week, -8.10% over the past six months, and -7.64% over the past one year.

Also Read: Penny stock hits 20% upper circuit after getting MPCB nod; distillery operations set to resume

Shareholding pattern of Gland Pharma

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	51.80%	51.80%	51.80%
FII	7.90%	7.40%	6.90%
DII	32.60%	32.90%	33.30%
Public	7.60%	7.90%	8.00%

About Gland Pharma

Gland Pharma Limited (NSE: GLAND), established in 1978, is a global injectable-focused pharmaceutical company producing vials, ampoules, pre-filled syringes, ophthalmic solutions, and oncology products across 60 countries.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs